Download Files:

BIO-1211

SKU HY-14126-1 mg Category Tags , ,

$140$560

Products Details

Product Description

– BIO-1211 is a highly selective and orally active α4β1 (VLA-4) inhibitor, with IC50 values of 4 nM and 2 μM for α4β1 and α4β7, respectively[1][2][3].

Web ID

– HY-14126

Storage Temperature

– -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

Shipping

– Blue Ice

Applications

– COVID-19-immunoregulation

Molecular Formula

– C36H48N6O9

References

– [1]L L Chen, et al. Multiple activation states of integrin alpha4beta1 detected through their different affinities for a small molecule ligand. J Biol Chem. 1999 May 7;274(19):13167-75.|[2]Nourollah Ramroodi, et al. Prophylactic Effect of BIO-1211 Small-Molecule Antagonist of VLA-4 in the EAE Mouse Model of Multiple Sclerosis. Immunol Invest. 2015;44(7):694-712.|[3]K c Lin, et al. Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses. J Med Chem. 1999 Mar 11;42(5):920-34.

CAS Number

– 187735-94-0

Molecular Weight

– 708.80

Compound Purity

– 99.94

SMILES

– O=C(O)[C@H]1N(C([C@H](C(C)C)NC([C@H](CC(O)=O)NC([C@H](CC(C)C)NC(CC2=CC=C(NC(NC3=CC=CC=C3C)=O)C=C2)=O)=O)=O)=O)CCC1

Clinical Information

– No Development Reported

Research Area

– Inflammation/Immunology

Solubility

– DMSO : 250 mg/mL (ultrasonic)

Target

– Integrin

Isoform

– α4β1;α4β7

Pathway

– Cytoskeleton

Product type

– Peptides

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.